pulmonary embolism

This page shows the latest pulmonary embolism news and features for those working in and with pharma, biotech and healthcare.

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

as pulmonary embolism (PE) or deep vein thrombosis (DVT) and an uncompetitive dose.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

baricitinib’s potential to cause side effects such as pulmonary embolism and venous thromboembolism.
AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

There was a fatality from a stroke in the trial in a patient, plus one case of a pulmonary embolism, although AbbVie said these occurred in at-risk patients.
Xarelto beats aspirin for recurrent blood clots

Janssen's parent company Johnson &Johnson (J&J) said in a statement that up to 10% of people who have suffered a VTE (usually a deep vein thrombosis or pulmonary embolism)
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE has backed Daiichi Sankyo's Lixiana (edoxaban) in final guidance as a treatment for adults with deep vein thrombosis and pulmonary embolism. ... NICE concluded that Lixiana was a cost-effective use of NHS resources for deep vein thrombosis (DVT) and
Daiichi’s new anticoagulant recommended by NICE

Specifically, in draft guidance NICE is minded to recommend Lixiana (edoxaban) as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more ... NICE has already recommended Lixiana for the

More from news
Approximately 4 fully matching, plus 55 partially matching documents found.

Modern anticoagulants threaten status quo

embolism in patients with AF and for the prevention of VTE in patients undergoing knee or hip replacement surgery. ... In one phase III trial, idrabiotaparinux sodium was non-inferior to warfarin in preventing the recurrent VTE at three months in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Thrombectomy System Market: Global Industry Analysis and Opportunity Assessment by 2025

Due to its versatility, the thrombectomy system can be utilized in several different applications like acute myocardial infraction (AMI), peripheral arterial disease (PAD), deep vein thrombosis (DVT), pulmonary embolism (PE), and
Future Trends and Growth Analysis of Micro Guide Catheters Market by 2025

Micro guide catheter tips are capable of reaching intricate anatomy to treat diseases such as uterine fibroids, arterial embolism, venal or pulmonary embolism, vascular malformations and hypervascularized tumors.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...